NLRP3 and hepatocellular carcinoma: Regarding drug resistance in HCC, inhibition of SIRT7 leads to depletion of dead-box helicase 3 X-liked (DDX3X), which can reverse acquired sorafenib resistance by hampering NLRP3 assembly.